tiprankstipranks
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market

SAB Biotherapeutics (SABS) Cash flow

56 Followers

SAB Biotherapeutics Cash Flow

SABS's free cash flow for Q3 2023 was $―. For the 2023 fiscal year, SABS's free cash flow was decreased by $-18.36M and operating cash flow was $-5.17M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
$ -11.46M$ -23.46M$ 3.76M$ 10.00M$ -9.21M
Investing Cash Flow
$ -202.59K$ -2.09M$ -10.94M$ -12.72M$ -608.75K
Financing Cash Flow
$ 5.75M$ 1.05M$ 34.12M$ 8.98M$ 3.68M
Cash Flow From Discontinued Operation
-----
Other Cash Adjustment Inside Changein Cash
-----
End Cash Position
$ 13.26M$ 15.05M$ 39.55M$ 12.61M$ 6.35M
Income Tax Paid Supplemental Data
-----
Interest Paid Supplemental Data
$ 337.55K-$ 294.46K$ 469.15K$ 428.48K
Issuance Of Capital Stock
-$ 7.68M-$ 9.90M$ 4.30M
Issuance Of Debt
$ -868.21K$ -3.66M$ -203.12K$ 661.61K$ 0.00
Repayment Of Debt
$ -3.03M$ -2.42M$ -203.12K$ -1.58M$ -623.27K
Free Cash Flow
$ -6.45M$ -25.55M$ -7.19M$ -2.73M$ -9.82M
Domestic Sales
-----
Foreign Sales
-----
Currency in USD

SAB Biotherapeutics Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis